Element Solutions vs Chemours: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Element Solutions Inc (ESI)

Q3 20266 Jul – 31 Jul 2026

▲4

Solstice's $14.5B buyout and record Q2 results drive ESI

Solstice to acquire ESI at a 15% premium Solstice Advanced Materials agreed to buy Element Solutions for $14.5 billion, or about $50.10 per share, a 15% premium. ESI holders get $10 cash plus 0.5 Solstice shares per share. This locks in a higher value for ESI and supports the stock price.
The acquisition is the main event setting a floor and premium for ESI shares.
Record Q2 sales and raised 2026 profit outlook ESI reported record Q2 net sales of $977.9 million, up 56%, with profit rising to $77.3 million. Electronics revenue jumped 75% on AI data center and semiconductor demand. Management raised full-year 2026 adjusted EBITDA guidance to $690–710 million, signaling confidence.
Strong results and higher guidance show the business is performing well, supporting the stock.
Q2 earnings beat estimates, stock up 49.8% YTD ESI beat Q2 earnings and revenue estimates, with adjusted EPS of $0.47 versus $0.43 expected. Revenue topped consensus by 11.5%. The company has now beaten estimates for four straight quarters. Shares have gained about 49.8% this year, far outpacing the S&P 500.
Consistent beats and strong stock performance reinforce positive momentum.
Solstice raises 2026 guidance, cites ESI deal Solstice, the buyer, reported strong Q2 sales of $1.15 billion and raised its full-year 2026 outlook. Its CEO highlighted the pending ESI acquisition as key to building an advanced materials platform with more electronics and AI exposure. A healthier buyer reduces deal risk.
A financially strong acquirer makes the pending merger more likely to close smoothly.

July 20266 Jul – 31 Jul 2026

▲4

Solstice's $14.5B buyout and record Q2 results drive ESI

Solstice to acquire ESI at a 15% premium Solstice Advanced Materials agreed to buy Element Solutions for $14.5 billion, or about $50.10 per share, a 15% premium. ESI holders get $10 cash plus 0.5 Solstice shares per share. This locks in a higher value for ESI and supports the stock price.
The acquisition is the main event setting a floor and premium for ESI shares.
Record Q2 sales and raised 2026 profit outlook ESI reported record Q2 net sales of $977.9 million, up 56%, with profit rising to $77.3 million. Electronics revenue jumped 75% on AI data center and semiconductor demand. Management raised full-year 2026 adjusted EBITDA guidance to $690–710 million, signaling confidence.
Strong results and higher guidance show the business is performing well, supporting the stock.
Q2 earnings beat estimates, stock up 49.8% YTD ESI beat Q2 earnings and revenue estimates, with adjusted EPS of $0.47 versus $0.43 expected. Revenue topped consensus by 11.5%. The company has now beaten estimates for four straight quarters. Shares have gained about 49.8% this year, far outpacing the S&P 500.
Consistent beats and strong stock performance reinforce positive momentum.
Solstice raises 2026 guidance, cites ESI deal Solstice, the buyer, reported strong Q2 sales of $1.15 billion and raised its full-year 2026 outlook. Its CEO highlighted the pending ESI acquisition as key to building an advanced materials platform with more electronics and AI exposure. A healthier buyer reduces deal risk.
A financially strong acquirer makes the pending merger more likely to close smoothly.

Latest6 Jul – 31 Jul 2026

▲4

Solstice's $14.5B buyout and record Q2 results drive ESI

Solstice to acquire ESI at a 15% premium Solstice Advanced Materials agreed to buy Element Solutions for $14.5 billion, or about $50.10 per share, a 15% premium. ESI holders get $10 cash plus 0.5 Solstice shares per share. This locks in a higher value for ESI and supports the stock price.
The acquisition is the main event setting a floor and premium for ESI shares.
Record Q2 sales and raised 2026 profit outlook ESI reported record Q2 net sales of $977.9 million, up 56%, with profit rising to $77.3 million. Electronics revenue jumped 75% on AI data center and semiconductor demand. Management raised full-year 2026 adjusted EBITDA guidance to $690–710 million, signaling confidence.
Strong results and higher guidance show the business is performing well, supporting the stock.
Q2 earnings beat estimates, stock up 49.8% YTD ESI beat Q2 earnings and revenue estimates, with adjusted EPS of $0.47 versus $0.43 expected. Revenue topped consensus by 11.5%. The company has now beaten estimates for four straight quarters. Shares have gained about 49.8% this year, far outpacing the S&P 500.
Consistent beats and strong stock performance reinforce positive momentum.
Solstice raises 2026 guidance, cites ESI deal Solstice, the buyer, reported strong Q2 sales of $1.15 billion and raised its full-year 2026 outlook. Its CEO highlighted the pending ESI acquisition as key to building an advanced materials platform with more electronics and AI exposure. A healthier buyer reduces deal risk.
A financially strong acquirer makes the pending merger more likely to close smoothly.

Chemours Co (CC)

Q3 202624 Jun – 7 Aug 2026

▲2▼2

Chemours settles PFAS suits, sets 2026 guidance; new state lawsuits add risk

EPA PFAS settlement removes major regulatory overhang Chemours agreed to pay a $22.5 million penalty and fund $90 million in PFAS mitigation projects, resolving a major federal dispute. The stock jumped 6.1% on the news as investors saw the settlement as a known cost that clears a big legal cloud, making future cash flows more predictable.
This is the period's biggest positive catalyst, directly lifting CC shares by reducing uncertainty.
New York and other states sue over PFAS contamination New York State sued 3M, DuPont, and Chemours spinoffs over PFAS, seeking cleanup costs and penalties. This adds fresh legal risk and potential future payouts, which can weigh on CC's stock because investors worry about unknown liabilities and cash outflows.
It introduces a new legal threat that could increase costs and uncertainty for CC.
2026 guidance shows earnings growth and deleveraging Chemours guided 2026 adjusted EBITDA to $775–$825 million and net leverage to about 3.8x, with Q2 beating expectations on pricing strength and cost cuts. This signals improving profits and a stronger balance sheet, supporting a higher stock price as investors gain confidence in the business.
It provides a forward-looking financial picture that directly influences CC's valuation.
Court approves $2.5 billion New Jersey PFAS settlements A federal judge approved over $2.5 billion in PFAS settlements involving DuPont, 3M, Chemours, and Corteva. While this resolves some claims, it confirms large legacy costs for Chemours, which can pressure the stock as investors factor in the cash outflows.
It finalizes a major liability that affects CC's financial obligations and investor sentiment.

July 202624 Jun – 7 Aug 2026

▲2▼2

Chemours settles PFAS suits, sets 2026 guidance; new state lawsuits add risk

EPA PFAS settlement removes major regulatory overhang Chemours agreed to pay a $22.5 million penalty and fund $90 million in PFAS mitigation projects, resolving a major federal dispute. The stock jumped 6.1% on the news as investors saw the settlement as a known cost that clears a big legal cloud, making future cash flows more predictable.
This is the period's biggest positive catalyst, directly lifting CC shares by reducing uncertainty.
New York and other states sue over PFAS contamination New York State sued 3M, DuPont, and Chemours spinoffs over PFAS, seeking cleanup costs and penalties. This adds fresh legal risk and potential future payouts, which can weigh on CC's stock because investors worry about unknown liabilities and cash outflows.
It introduces a new legal threat that could increase costs and uncertainty for CC.
2026 guidance shows earnings growth and deleveraging Chemours guided 2026 adjusted EBITDA to $775–$825 million and net leverage to about 3.8x, with Q2 beating expectations on pricing strength and cost cuts. This signals improving profits and a stronger balance sheet, supporting a higher stock price as investors gain confidence in the business.
It provides a forward-looking financial picture that directly influences CC's valuation.
Court approves $2.5 billion New Jersey PFAS settlements A federal judge approved over $2.5 billion in PFAS settlements involving DuPont, 3M, Chemours, and Corteva. While this resolves some claims, it confirms large legacy costs for Chemours, which can pressure the stock as investors factor in the cash outflows.
It finalizes a major liability that affects CC's financial obligations and investor sentiment.

Latest24 Jun – 7 Aug 2026

▲2▼2

Chemours settles PFAS suits, sets 2026 guidance; new state lawsuits add risk

EPA PFAS settlement removes major regulatory overhang Chemours agreed to pay a $22.5 million penalty and fund $90 million in PFAS mitigation projects, resolving a major federal dispute. The stock jumped 6.1% on the news as investors saw the settlement as a known cost that clears a big legal cloud, making future cash flows more predictable.
This is the period's biggest positive catalyst, directly lifting CC shares by reducing uncertainty.
New York and other states sue over PFAS contamination New York State sued 3M, DuPont, and Chemours spinoffs over PFAS, seeking cleanup costs and penalties. This adds fresh legal risk and potential future payouts, which can weigh on CC's stock because investors worry about unknown liabilities and cash outflows.
It introduces a new legal threat that could increase costs and uncertainty for CC.
2026 guidance shows earnings growth and deleveraging Chemours guided 2026 adjusted EBITDA to $775–$825 million and net leverage to about 3.8x, with Q2 beating expectations on pricing strength and cost cuts. This signals improving profits and a stronger balance sheet, supporting a higher stock price as investors gain confidence in the business.
It provides a forward-looking financial picture that directly influences CC's valuation.
Court approves $2.5 billion New Jersey PFAS settlements A federal judge approved over $2.5 billion in PFAS settlements involving DuPont, 3M, Chemours, and Corteva. While this resolves some claims, it confirms large legacy costs for Chemours, which can pressure the stock as investors factor in the cash outflows.
It finalizes a major liability that affects CC's financial obligations and investor sentiment.